Orexo

Orexo reports a larger net loss for Q2 with revenue of SEK 3.50 million, well below the consensus estimate of SEK 5 million; earnings per share -2.92 SEK, EBIT -103.3 million SEK and EBITDA -95.1 million SEK. Revenue declined year‑on‑year, and higher operating expenses reflect ongoing R&D spending and organizational adjustments following the sale of Zubsolv in the US. The company is advancing its emergency‑medication pipeline, notes external interest in the AmorphOX technology and is holding partnership talks. Orexo plans a regulatory‑relevant study for OX640 from Q4 2026 with results in Q1 2027, intends to refile the NDA for Izipry in Q3 2026 and targets a possible FDA approval in Q1 2027. To support growth and clarify DOJ matters, Orexo is exploring additional financing options. » Altro su de.investing.com

Orexo reported third-quarter net sales of SEK 119 million versus expected SEK 128.1 million and recorded a negative EBITDA of SEK 9.8 million. The share fell 14.8% to SEK 31.9 after the figures; the company cites currency effects and seasonally reduced wholesale inventories as reasons. Despite the short-term weakness, Orexo highlights progress on its AmorphOX platform, including promising preclinical data for the intranasal semaglutide program OX472 and a USD 50.9 million BARDA funding award for the emergency program OX390. Liquidity fell to SEK 105.6 million, but management reconfirms the annual outlook and still aims for positive EBITDA in 2025. » Altro su de.investing.com

Orexo AB reported revenue of SEK 180 million in the second quarter of 2025, significantly surpassing forecasts, but the stock still declined by 6.17%. Despite an improved gross margin and strong performance in the US market, EBITDA remains negative, indicating ongoing financial challenges and cautious investor sentiment. CEO Nikolay Sorensen emphasized the company's focus on cost discipline and patient access, while maintaining a positive EBITDA outlook for the full year. » Altro su de.investing.com